REGENXBIO

Roche building

Fewer doses give Roche's Vabysmo an edge over powerhouse Eylea

After two years on Roche's Vabysmo, more than 60% of wet age-related macular degeneration (AMD) patients could be treated every four months.

Kevin Dunleavy Jul 14, 2022 8:45am

Regenxbio Rockville Md

Regenxbio set for commercial era with new plant, AbbVie deal

Jul 12, 2022 9:15am

Regenxbio new gene therapy plant

Regenxbio debuts $65M gene therapy manufacturing facility

Jun 14, 2022 9:55am

Gene therapy

Here comes the gene therapy wave. What now?

Oct 21, 2021 8:00am